Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant

References

• Ebvallo (tabelecleucel) Summary of Product Characteristics. [Internet]. Pierre Fabre; 2022 [cited 2023 Jun 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/ebvallo-epar-product-information_en.pdf
   Google Scholar
• Mahadeo KM, Baiocchi R, Beitinjaneh A, et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. 2024;25(3):376–387. doi:10.1016/s1470-2045(23)00649-6.
   PubMed Web of Science ®Google Scholar
• Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–562. doi:10.1056/NEJMra1702693.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni JF, Jr., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–1901. doi:10.1001/jama.2011.1592.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001. doi:10.1182/blood-2008-09-178046.
   PubMed Web of Science ®Google Scholar
• Dierickx D, Tousseyn T, Sagaert X, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54(11):2433–2440. doi:10.3109/10428194.2013.780655.
   PubMed Web of Science ®Google Scholar
• García-Cadenas I, Yáñez L, Jarque I, et al. Frequency, characteristics, and outcome of PTLD after allo-SCT: a multicenter study from the Spanish group of blood and marrow transplantation (GETH). Eur J Haematol. 2019;102(6):465–471. doi:10.1111/ejh.13226.
   PubMed Web of Science ®Google Scholar
• Socié G, Barba P, Barlev A, et al. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. Bone Marrow Transplant. 2024;59(1):52–58. doi:10.1038/s41409-023-02127-9.
   PubMed Web of Science ®Google Scholar
• Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–811. doi:10.3324/haematol.2016.144428.
   PubMed Web of Science ®Google Scholar
• Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48. doi:10.1097/txd.0000000000000557.
   PubMed Web of Science ®Google Scholar
• Baker A, Frauca Remacha E, Torres Canizales J, et al. Current practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: results of ERN TransplantChild Healthcare Working Group Survey. Children (Basel). 2021;8(8):661. doi:10.3390/children8080661.
   PubMed Web of Science ®Google Scholar
• Jagadeesh D, Tsai DE, Wei W, et al. Post-transplant lymphoproliferative disorder (PTLD) after solid organ transplant (SOT): a multicenter real world analysis (RWA) of 877 patients (pts) treated in the modern era. J Clin Oncol. 2020;38(15_suppl):e20026. doi:10.1200/JCO.2020.38.15_suppl.e20026.
   Web of Science ®Google Scholar
• Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017;35(5):536–543. doi:10.1200/jco.2016.69.3564.
   PubMed Web of Science ®Google Scholar
• Dharnidharka V, Thirumalai D, Jaeger U, et al. Clinical outcomes of solid organ transplant patients with Epstein-Barr virus-driven (EBV+) post-transplant lymphoproliferative disorder (PTLD) who fail rituximab plus chemotherapy: a multinational, retrospective chart review study. Blood. 2021;138(Suppl 1):2528–2528. doi:10.1182/blood-2021-147307.
   Google Scholar
• Allen UD, Preiksaitis JK. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652. doi:10.1111/ctr.13652.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109(11):djx187. doi:10.1093/jnci/djx187.
   Google Scholar
• Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003;14(6):680–686. doi:10.1097/01.EDE.0000081989.82616.7d.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The Central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55. doi:10.1093/biomet/70.1.41.
   Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79(387):516–524. doi:10.1080/01621459.1984.10478078.
   Web of Science ®Google Scholar
• Brookhart MA, Wyss R, Layton JB, et al. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604–611. doi:10.1161/circoutcomes.113.000359.
   PubMed Web of Science ®Google Scholar
• Brookhart MA. Counterpoint: the treatment decision design. Am J Epidemiol. 2015;182(10):840–845. doi:10.1093/aje/kwv214.
   PubMed Web of Science ®Google Scholar
• Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408):1074–1078. doi:10.1080/01621459.1989.10478874.
   Web of Science ®Google Scholar